Mednax Inc

Healthcare US MD

19.46USD
-0.33(1.67%)

Last update at 2026-03-12T20:00:00Z

Day Range

19.2919.95
LowHigh

52 Week Range

8.1817.30
LowHigh

Fundamentals

  • Previous Close 19.79
  • Market Cap801.59M
  • Volume976284
  • P/E Ratio9.00
  • Dividend Yield0.37%
  • EBITDA210.67M
  • Revenue TTM2012.04M
  • Revenue Per Share TTM24.55
  • Gross Profit TTM 467.03M
  • Diluted EPS TTM1.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 81.37M 135.23M 7.15M -1241.98000M 368.84M
Minority interest 0.00400M 0.03M 0.23M 0.23M 0.23M
Net income 66.33M 130.96M -9.58000M -1150.09400M 268.63M
Selling general administrative 231.40M 263.36M 248.95M 404.64M 432.38M
Selling and marketing expenses - - - - -
Gross profit 467.03M 513.24M 449.32M 892.00M 989.51M
Reconciled depreciation 35.64M 32.15M 28.44M 78.86M 111.28M
Ebit 172.69M 202.92M 173.52M 416.27M 452.67M
Ebitda 237.36M 251.80M 201.96M 495.13M 563.95M
Depreciation and amortization 64.67M 48.88M 28.44M 78.86M 111.28M
Non operating income net other -56.67400M 15.56M 19.50M - 11.76M
Operating income 172.69M 202.92M 173.52M 416.27M 445.85M
Other operating expenses 1772.02M 1693.45M 1562.02M 3105.05M 3201.28M
Interest expense 39.70M 68.72M 110.48M 119.38M 88.77M
Tax provision 18.81M 27.24M 16.73M -91.88600M 100.21M
Interest income 34.30M 53.16M 90.98M 105.93M 76.75M
Net interest income -39.69500M -68.72200M -110.48200M -119.38100M -88.76900M
Extraordinary items 3.77M 22.95M -786.90800M -347.60800M 10.02M
Non recurring 27.31M 22.10M 73.80M - -
Other items - - - - -
Income tax expense 18.81M 27.24M 16.73M -91.88600M 100.21M
Total revenue 1972.02M 1911.19M 1733.95M 3513.54M 3647.12M
Total operating expenses 267.03M 295.50M 277.39M 483.50M 543.66M
Cost of revenue 1504.99M 1397.95M 1284.63M 2621.54M 2657.62M
Total other income expense net -91.31800M -67.69000M -166.37000M -1658.25400M 11.76M
Discontinued operations 3.77M 22.95M -786.90800M -1539.91000M 10.02M
Net income from continuing ops 62.56M 107.99M -9.58000M -1150.09400M 268.63M
Net income applicable to common shares 66.33M 130.96M -796.48800M -1497.70200M 268.63M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2347.89M 2722.55M 3347.95M 4145.90M 5934.91M
Intangible assets 18.49M 21.57M 26.64M 274.41M 588.31M
Earning assets - - - - -
Other current assets 28.14M 51.68M 78.70M 45.36M 56.47M
Total liab 1456.26M 1825.85M 2600.23M 2646.91M 2847.03M
Total stockholder equity 891.63M 896.69M 747.72M 1499.00M 3087.88M
Deferred long term liab 33.64M 41.41M 61.75M - 131.24M
Other current liab 199.96M -22.17400M -21.15200M -23.44700M 469.13M
Common stock 0.83M 0.86M 0.86M 0.84M 0.88M
Capital stock 0.83M 0.86M 0.86M 0.84M 0.88M
Retained earnings -89.06300M -155.39000M -286.35400M 510.21M 2094.36M
Other liab 348.68M 365.91M 372.37M 330.21M 372.55M
Good will 1834.48M 1794.96M 1715.99M 3057.16M 4689.19M
Other assets 229.10M 219.37M 217.80M 1776.87M 777.16M
Cash 9.82M 387.39M 1123.84M 112.77M 36.74M
Cash and equivalents 9.82M 387.39M 1123.84M 112.77M 25.49M
Total current liabilities 374.23M 394.12M 423.16M 511.87M 469.34M
Current deferred revenue 105.92M - - - -469.38700M
Net debt 743.74M 678.44M 680.87M 1707.98M 1937.79M
Short term debt 36.49M 22.17M 21.15M 23.45M 0.25M
Short long term debt 14.90M - - - -
Short long term debt total 753.57M 1065.83M 1804.71M 1820.75M 1974.53M
Other stockholder equity 983.60M 1049.90M 1029.68M 987.94M 1200.46M
Property plant equipment 73.29M 70.15M 76.19M 129.09M 133.04M
Total current assets 334.75M 740.85M 1549.35M 657.00M 657.41M
Long term investments 93.24M 99.72M - 74.51M 69.70M
Net tangible assets 891.63M 896.49M -757.12500M -9.44100M -1883.42300M
Short term investments 93.24M 99.72M 104.87M 74.51M 21.92M
Net receivables 296.79M 301.77M 241.93M 498.87M 542.27M
Long term debt 636.38M 1002.26M 1742.59M 1730.24M 1974.28M
Inventory - - - - -
Accounts payable 31.86M 394.12M 423.16M 511.87M 469.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 0.20M 0.23M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.73500M 1.32M 3.53M -202.10200M -207.81600M
Additional paid in capital - - - - -
Common stock total equity 0.83M 0.86M 0.86M 0.84M 0.88M
Preferred stock total equity - - - - -
Retained earnings total equity -89.06300M -155.39000M -286.35400M - 2094.36M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -105.92500M -88.34400M 107.36M -162.38500M -333.97600M
Deferred long term asset charges - - - - -
Non current assets total 2013.14M 1981.70M 1798.60M 3488.90M 5277.50M
Capital lease obligations 65.80M 63.57M 71.02M 90.51M 0.25M
Long term debt total 636.38M 1002.26M 1742.59M 1730.30M 1974.28M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -56.95400M 1.44M -28.41300M 102.45M -2.17400M
Change to liabilities -1.35400M -3.47700M 44.49M 46.20M -50.16000M
Total cashflows from investing activities -56.95400M -53.07300M 815.51M 102.45M -142.76900M
Net borrowings -401.50100M -759.84800M -1.67100M -239.50000M 120.55M
Total cash from financing activities -487.55400M -760.11600M -4.15800M -393.07000M -170.61100M
Change to operating activities 18.73M 30.32M -26.18600M -12.55600M -15.54600M
Net income 62.57M 108.01M -9.58000M -1150.09400M 268.63M
Change in cash -377.56700M -736.45200M 1015.97M 56.02M -23.45500M
Begin period cash flow 387.39M 1123.84M 107.87M 56.74M 80.20M
End period cash flow 9.82M 387.39M 1123.84M 112.77M 56.74M
Total cash from operating activities 166.94M 76.74M 204.62M 346.64M 289.93M
Issuance of capital stock 5.40M 6.85M 7.01M 11.26M 16.26M
Depreciation 35.64M 32.15M 28.44M 78.86M 111.28M
Other cashflows from investing activities -26.78900M 84.87M 872.71M 152.69M -91.72700M
Dividends paid - - -526.25200M -1747.30000M 2223.50M
Change to inventory - - -54.88700M -34.11700M -66.72800M
Change to account receivables -5.54300M -72.73100M 37.94M 7.85M -36.59800M
Sale purchase of stock -88.51100M -4.71900M -8.49300M -145.28000M -302.16000M
Other cashflows from financing activities 1480.73M 0.41M 1052.24M 3475.29M 4434.65M
Change to netincome 31.38M -14.16200M 912.78M 1813.45M 3.65M
Capital expenditures 29.71M 32.25M 28.79M 31.88M 48.87M
Change receivables -5.54300M -72.73100M 37.94M - -36.59800M
Cash flows other operating 38.72M 52.84M -29.70400M - -11.45000M
Exchange rate changes - - - - -
Cash and cash equivalents changes -377.56700M -736.45200M 1015.97M - -23.45500M
Change in working capital 31.83M -23.35600M 52.73M 97.24M -97.11500M
Stock based compensation 16.13M 18.97M 39.04M 35.35M 38.70M
Other non cash items 43.55M -27.79700M 57.70M 1462.28M -7.42400M
Free cash flow 137.23M 44.49M 175.83M 314.76M 241.06M

Peer Comparison

Sector: Healthcare Industry: Medical Care Facilities

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MD
Mednax Inc
-0.33 1.67% 19.46 9.00 6.31 0.37 0.78 0.66 6.79
HCA
HCA Holdings Inc
-4.7 0.87% 532.58 13.19 13.66 1.13 293.44 1.77 8.22
FSNUY
Fresenius SE & Co KGaA ADR
-0.27 1.96% 13.48 16.87 9.44 0.42 0.78 0.79 5.37
FSNUF
Fresenius SE & Co. KGaA
- -% 54.35 16.76 9.62 0.42 0.79 0.78 5.31
JDHIY
JD Health International Inc
- -% 9.08 62.50 35.97 0.30 2.32 0.16 3.90

Reports Covered

Stock Research & News

Profile

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Mednax Inc

1301 Concord Terrace, Sunrise, FL, United States, 33323

Key Executives

Name Title Year Born
Mr. Mark S. Ordan CEO & Director 1959
Dr. Roger J. Medel M.D. Co-Founder & Director 1947
Mr. C. Marc Richards Exec. VP & CFO 1971
Mr. John C. Pepia Sr. VP & Chief Accounting Officer 1963
Ms. Mary Ann E. Moore Exec. VP and Chief Enterprise Risk & Legal Operations Officer 1960
Dr. James D. Swift M.D. Exec. VP & Chief Operating Officer NA
Ms. Cheryl M. VanPattan Sr. VP & Chief Information Officer NA
Mr. Charles W. Lynch C.F.A. Sr. VP of Fin., Strategy & Investor Relations NA
Ms. Dana Dreher-Rodwell VP & Chief Compliance Officer NA
Ms. Meghan K. Lublin Sr. VP, Chief Brand & Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.